AtherosclerosisNCT01581385
Acoustic Radiation Force Impulse (ARFI) Ultrasound for Noninvasive, Diagnostic Atherosclerosis Imaging
An observational study of Atherosclerosis, run by University of North Carolina, Chapel Hill at 1 site in United States.
Trial summary
This is a pilot clinical trial to assess the ability of a new ultrasound-based imaging method, Acoustic Radiation Force Impulse (ARFI) ultrasound, to describe the composition and structure of atherosclerotic plaques. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Atherosclerosis
- How many people
- 25 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2012to 31 May 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult (18 years or older) male and female patients scheduled to undergo clinically indicated carotid endarterectomy surgery.
Who may be able to join
- Patients scheduled to undergo clinically indicated carotid endarterectomy
- Determination of clinical need for carotid endarterectomy will be made by the vascular surgeons on this protocol, but the general criteria include symptomatic carotid disease with a stenosis or lesion in the carotid artery thought to be the source of emboli or asymptomatic carotid artery disease with a > 60% internal carotid artery stenosis in the ipsilateral (surgical) artery.
- Male or Female
- >18 years of age with no upper limit
- Ability to provide informed consent
- Surgeon's approval
- Any ethnicity or race (meeting all other criteria)
Who cannot join
- Inability to communicate in English
- Inability to provide valid consent
- Inability to remain motionless for at least 15 minutes
- Carotid arteries deeper than 35 mm
- Pregnancy*
- Pregnant women will be excluded from this study because carotid dissection is more likely than carotid plaque in women of child-bearing age.
Trial locations and contacts
1 site in 1 country.
United States1 site
The University of North Carolina at Chapel Hill Hospitals
Chapel Hill, North Carolina, 27599
About this study
Official title: Acoustic Radiation Force Impulse (ARFI) Ultrasound for Noninvasive, Diagnostic Atherosclerosis Imaging; Independent Scientist: ARFI and RWI Ultrasound for Improved Atherosclerosis Imaging
This is a pilot clinical trial to assess the ability of a new ultrasound-based imaging method, Acoustic Radiation Force Impulse (ARFI) ultrasound, to describe the composition and structure of atherosclerotic plaques. The hypothesis being tested is that in vivo, transcutaneous ARFI ultrasound delineates plaque composition and structure in human carotid arteries.
Read the detailed description
The purpose of this study is to evaluate Acoustic Radiation Force Impulse (ARFI) ultrasound imaging for describing the composition and structure of atherosclerotic plaques. The surgical atherosclerotic plaques of 16 patient volunteers undergoing clinically indicated carotid endarterectomy (surgical removal of plaque from the carotid artery) will be imaged preoperatively by ARFI. ARFI imaging will occur during the volunteers' preoperative workup visits (inpatient or outpatient), in the surgical holding area (inpatient or outpatient), or at the patient bedside (inpatient). Then, the routinely excised plaque specimens will be sent for histopathological processing to determine plaque composition and structure. The histopathological data will be used to validate ARFI imaging performance for plaque material and structural characterization. This will end the participant's involvement in the study.
There are two experimental components to this study beyond what is standard practice for carotid endarterectomy patients: 1) preoperative ARFI ultrasound imaging of ipsilateral (surgical) carotid arteries, and 2) submission of sections of the carotid plaque excised intraoperatively to the UNC Hospitals clinical laboratories for immunohistochemical analysis.
This study will commence with ARFI ultrasound imaging at the time of the patient volunteer's preoperative workup for carotid endarterectomy surgery (outpatients and inpatients), while the patient is in the holding area for surgery (outpatients and inpatients), or at the patient bedside (inpatients). If the patient volunteer is an outpatient, ARFI ultrasound imaging will be performed up to two weeks prior to surgery. Preoperative ARFI ultrasound imaging will be performed in addition to the patient volunteer's routine preoperative duplex ultrasound and any other exams used to determine if carotid endarterectomy is clinically indicated.
ARFI ultrasound is a noninvasive diagnostic imaging technology performed using commercially available clinical ultrasound imaging equipment - the Siemens SONOLINE or Acuson Antares imaging systems equipped for research purposes and VF10-5 or VF7-3 linear array transducers (Siemens Medical Solutions, USA Inc. Ultrasound Division). ARFI imaging will be carried out by a professional sonographer trained in peripheral vascular ultrasound and faculty (Caterina Gallippi, Ph.D., Associate Professor, study PI) and/or graduate student research assistants in the UNC-CH Joint Department of Biomedical Engineering. The sonographer will acquire ARFI ultrasound data with matched B-Mode (for anatomical reference) in ipsilateral (surgical) carotid arteries of patient volunteers. Patient volunteers will be asked to lie on an examination table (outpatients) or to remain in their hospital beds (inpatients). The head of the exam table/bed may be raised to an approximate 45 degree angle to best visualize the carotid arteries with ultrasound imaging.
Once the patient volunteer is positioned, ultrasound gel will be applied to the patient volunteer's neck. The ultrasound imaging transducer will then be placed on top of the gel. Once the carotid artery is located, ARFI ultrasound imaging will begin. In the ipsilateral (surgical) carotid artery, the imaging field of view will be centered on the carotid plaque, with axial focal depth directed to the position of the near or far wall containing the thickest portion of the plaque. Data acquisitions will be gated to diastole. Two repeated acquisitions will be acquired for each of four ARFI imaging sequences. The position of landmarks such as arterial branch points and morphological features such as arterial wall thickness will be recorded for spatial registration to duplex ultrasound and histology.
The length of time for ARFI data collection in the carotid artery is estimated to be less than 30 minutes. Once the ipsilateral (surgical) carotid artery is imaged, the study procedure will be completed for the first portion of the study.
For the second part of the study, sections of the carotid plaque specimen routinely extracted during carotid endarterectomy surgery will be photographed and then fixed and paraffin embedded in the UNC Tissue Procurement core facility. The specimens will then undergo sectioning and staining in the UNC Histopathology core facility. These experimental sections will be in addition to the sections routinely sent for immunohistochemical processing after carotid endarterectomy. Sectioning will be directed by the surgeon per standard histopathology protocol and per laboratory sampling protocol. The sections will be stained with hematoxylin and eosin (H\&E) for baseline, Verhoeff van Giesen (VVG) for elastin, Sirius Red (SR) with polarized light microscopy for collagen sub-types I and III, von Kossa (VK) for calcium, and/or Lillie modification of Masson's trichrome (MT) for fibrin, or other comparable stains. This will conclude part two of the study. However, excised plaque specimens will be stored in Dr. Gallippi's (PI) laboratory for a period of up to five years following study completion. Their storage will enable re-sectioning as need to achieve proper spatial alignment with ARFI imaging. The stored specimens will not be used for future research; they are for verification purposes only. The specimens will be submerged in formalin and stored in sealed plastic containers. No identifiable information will be recorded with the samples, and all HIPAA guidelines and procedures will be observed.
Patient volunteers' participation will end once both study parts one (ARFI ultrasound imaging) and two (immunohistochemical processing of excised plaque specimens) are completed. Therefore, there will be no follow-up visits required or additional demands placed on the patient volunteers. A Patient volunteer is asked to consent to (1) ARFI ultrasound imaging of his/her ipsilateral (surgical) carotid arteries before his/her clinically indicated endarterectomy surgery, and (2) sections of his/her routinely excised plaques specimens undergoing immunohistochemical processing (in addition to any sections routinely sent for immunohistochemical processing after carotid endarterectomy). No additional procedures or requirements are proposed. Every other aspect of the volunteers' preoperative workup for surgery and the endarterectomy surgery itself will be carried out in the normal standard of care as clinically indicated.
There is no control group in this study. This is a pilot study to determine if ARFI ultrasound imaging in this patient population may be relevant to delineating the composition and structure of carotid plaques with immunohistochemical validation.
- Conditions
- Atherosclerosis
- Keywords
- atherosclerosis, carotid artery, carotid endarterectomy
- Medical subject headings
- Atherosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Carotid endarterectomy | Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery. |
What is being measured
The primary outcome is the main question the study is designed to answer.
ARFI AUC score
Statistical area under the curve (AUC) scores will be calculated using trained readers and spatially matched pathologist's interpretation of histochemical data. AUC scores will be determined for each of the four ARFI beam sequences implemented in this study with respect to characterizing calcium deposits, lipid/necrotic core, fibrous caps, collagen deposits, elastin deposits, disrupted internal elastic lamina, and thrombus.
Measured: baseline
Secondary outcomes (2)
ARFI sensitivity
Statistical sensitivity will be calculated by assessing the average AUC curve across all readers for each of the four ARFI beam sequences implemented in this study with respect to characterizing calcium deposits, lipid/necrotic core, fibrous caps, collagen deposits, elastin deposits, disrupted internal elastic lamina, and thrombus.
Measured: baseline
ARFI specificity
Statistical sensitivity will be calculated by assessing the average AUC curve across all readers for each of the four ARFI beam sequences implemented in this study with respect to characterizing calcium deposits, lipid/necrotic core, fibrous caps, collagen deposits, elastin deposits, disrupted internal elastic lamina, and thrombus.
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2012 (estimated)
- Study startApr 2012
- Primary completion31 May 2020
- Study completion31 May 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AtherosclerosisStudies of the same condition, open and under way.
- More trials run by University of North Carolina, Chapel HillThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Enrolment
- 25 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Responsible party
- Sponsor
- Investigators
- Caterina M Gallippi, Ph.D., Principal investigator, UNC Chapel Hill
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01581385
- Sponsor's protocol ID
- 09-1049
- Other IDs
- R01HL092944
- Status last verified
- May 2021
- First submitted
- 13 Mar 2012
- Last updated
- 17 May 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Acoustic Radiation Force Impulse (ARFI) Ultrasound for Noninvasive, Diagnostic Atherosclerosis Imaging; Independent Scientist: ARFI and RWI Ultrasound for Improved Atherosclerosis Imaging
- ClinicalTrials.gov ID
- NCT01581385
- Acronym / sponsor ID
- 09-1049
- Conditions
- Atherosclerosis
- Keywords
- atherosclerosis, carotid artery, carotid endarterectomy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 25 participants (actual)
- Lead sponsor
- University of North Carolina, Chapel HillUniversity, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- Study start
- Apr 2012
- Primary completion
- 31 May 2020 (actual)
- Study completion
- 31 May 2020 (actual)
- First posted
- 20 Apr 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a pilot clinical trial to assess the ability of a new ultrasound-based imaging method, Acoustic Radiation Force Impulse (ARFI) ultrasound, to describe the composition and structure of atherosclerotic plaques. The hypothesis being tested is that in vivo, transcutaneous ARFI ultrasound delineates plaque composition and structure in human carotid arteries.
Detailed description
The purpose of this study is to evaluate Acoustic Radiation Force Impulse (ARFI) ultrasound imaging for describing the composition and structure of atherosclerotic plaques. The surgical atherosclerotic plaques of 16 patient volunteers undergoing clinically indicated carotid endarterectomy (surgical removal of plaque from the carotid artery) will be imaged preoperatively by ARFI. ARFI imaging will occur during the volunteers' preoperative workup visits (inpatient or outpatient), in the surgical holding area (inpatient or outpatient), or at the patient bedside (inpatient). Then, the routinely excised plaque specimens will be sent for histopathological processing to determine plaque composition and structure. The histopathological data will be used to validate ARFI imaging performance for plaque material and structural characterization. This will end the participant's involvement in the study.
There are two experimental components to this study beyond what is standard practice for carotid endarterectomy patients: 1) preoperative ARFI ultrasound imaging of ipsilateral (surgical) carotid arteries, and 2) submission of sections of the carotid plaque excised intraoperatively to the UNC Hospitals clinical laboratories for immunohistochemical analysis.
This study will commence with ARFI ultrasound imaging at the time of the patient volunteer's preoperative workup for carotid endarterectomy surgery (outpatients and inpatients), while the patient is in the holding area for surgery (outpatients and inpatients), or at the patient bedside (inpatients). If the patient volunteer is an outpatient, ARFI ultrasound imaging will be performed up to two weeks prior to surgery. Preoperative ARFI ultrasound imaging will be performed in addition to the patient volunteer's routine preoperative duplex ultrasound and any other exams used to determine if carotid endarterectomy is clinically indicated.
ARFI ultrasound is a noninvasive diagnostic imaging technology performed using commercially available clinical ultrasound imaging equipment - the Siemens SONOLINE or Acuson Antares imaging systems equipped for research purposes and VF10-5 or VF7-3 linear array transducers (Siemens Medical Solutions, USA Inc. Ultrasound Division). ARFI imaging will be carried out by a professional sonographer trained in peripheral vascular ultrasound and faculty (Caterina Gallippi, Ph.D., Associate Professor, study PI) and/or graduate student research assistants in the UNC-CH Joint Department of Biomedical Engineering. The sonographer will acquire ARFI ultrasound data with matched B-Mode (for anatomical reference) in ipsilateral (surgical) carotid arteries of patient volunteers. Patient volunteers will be asked to lie on an examination table (outpatients) or to remain in their hospital beds (inpatients). The head of the exam table/bed may be raised to an approximate 45 degree angle to best visualize the carotid arteries with ultrasound imaging.
Once the patient volunteer is positioned, ultrasound gel will be applied to the patient volunteer's neck. The ultrasound imaging transducer will then be placed on top of the gel. Once the carotid artery is located, ARFI ultrasound imaging will begin. In the ipsilateral (surgical) carotid artery, the imaging field of view will be centered on the carotid plaque, with axial focal depth directed to the position of the near or far wall containing the thickest portion of the plaque. Data acquisitions will be gated to diastole. Two repeated acquisitions will be acquired for each of four ARFI imaging sequences. The position of landmarks such as arterial branch points and morphological features such as arterial wall thickness will be recorded for spatial registration to duplex ultrasound and histology.
The length of time for ARFI data collection in the carotid artery is estimated to be less than 30 minutes. Once the ipsilateral (surgical) carotid artery is imaged, the study procedure will be completed for the first portion of the study.
For the second part of the study, sections of the carotid plaque specimen routinely extracted during carotid endarterectomy surgery will be photographed and then fixed and paraffin embedded in the UNC Tissue Procurement core facility. The specimens will then undergo sectioning and staining in the UNC Histopathology core facility. These experimental sections will be in addition to the sections routinely sent for immunohistochemical processing after carotid endarterectomy. Sectioning will be directed by the surgeon per standard histopathology protocol and per laboratory sampling protocol. The sections will be stained with hematoxylin and eosin (H\&E) for baseline, Verhoeff van Giesen (VVG) for elastin, Sirius Red (SR) with polarized light microscopy for collagen sub-types I and III, von Kossa (VK) for calcium, and/or Lillie modification of Masson's trichrome (MT) for fibrin, or other comparable stains. This will conclude part two of the study. However, excised plaque specimens will be stored in Dr. Gallippi's (PI) laboratory for a period of up to five years following study completion. Their storage will enable re-sectioning as need to achieve proper spatial alignment with ARFI imaging. The stored specimens will not be used for future research; they are for verification purposes only. The specimens will be submerged in formalin and stored in sealed plastic containers. No identifiable information will be recorded with the samples, and all HIPAA guidelines and procedures will be observed.
Patient volunteers' participation will end once both study parts one (ARFI ultrasound imaging) and two (immunohistochemical processing of excised plaque specimens) are completed. Therefore, there will be no follow-up visits required or additional demands placed on the patient volunteers. A Patient volunteer is asked to consent to (1) ARFI ultrasound imaging of his/her ipsilateral (surgical) carotid arteries before his/her clinically indicated endarterectomy surgery, and (2) sections of his/her routinely excised plaques specimens undergoing immunohistochemical processing (in addition to any sections routinely sent for immunohistochemical processing after carotid endarterectomy). No additional procedures or requirements are proposed. Every other aspect of the volunteers' preoperative workup for surgery and the endarterectomy surgery itself will be carried out in the normal standard of care as clinically indicated.
There is no control group in this study. This is a pilot study to determine if ARFI ultrasound imaging in this patient population may be relevant to delineating the composition and structure of carotid plaques with immunohistochemical validation.
Study design
- Observational model
- Case only
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Carotid endarterectomy | – | –Adult patient volunteers, male and female, undergoing clinically indicated carotid endarterectomy surgery. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult (18 years or older) male and female patients scheduled to undergo clinically indicated carotid endarterectomy surgery.
Key inclusion criteria (7 listed)
- Patients scheduled to undergo clinically indicated carotid endarterectomy
- Determination of clinical need for carotid endarterectomy will be made by the vascular surgeons on this protocol, but the general criteria include symptomatic carotid disease with a stenosis or lesion in the carotid artery thought to be the source of emboli or asymptomatic carotid artery disease with a > 60% internal carotid artery stenosis in the ipsilateral (surgical) artery.
- Male or Female
- >18 years of age with no upper limit
- Ability to provide informed consent
Key exclusion criteria (6 listed)
- Inability to communicate in English
- Inability to provide valid consent
- Inability to remain motionless for at least 15 minutes
- Carotid arteries deeper than 35 mm
- Pregnancy*
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
ARFI AUC score
Time frame: baseline
Statistical area under the curve (AUC) scores will be calculated using trained readers and spatially matched pathologist's interpretation of histochemical data. AUC scores will be determined for each of the four ARFI beam sequences implemented in this study with respect to characterizing calcium deposits, lipid/necrotic core, fibrous caps, collagen deposits, elastin deposits, disrupted internal elastic lamina, and thrombus.
2 secondary outcomes
ARFI sensitivity
Time frame: baseline
ARFI specificity
Time frame: baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 May 2021.
Related trials for Atherosclerosis
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Active, not recruiting
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Peripheral Artery Disease
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingPhase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
Peripheral Artery Disease (PAD)
Recruiting
The THOR IDE Study
Peripheral Artery Disease, Peripheral Artery Stenosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Caterina M Gallippi, Ph.D. principal investigator
UNC Chapel Hill
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Atherosclerosis, run by University of North Carolina, Chapel Hill at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ARFI AUC score (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 May 2021.